The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis

The remarkable clinical efficacy of anti-CD20 monoclonal antibodies (mAb) in relapsing-remitting multiple sclerosis points at the critical involvement of B cells in the disease. However, the exact pathogenic contribution of B cells is poorly understood. In this publication we review new data on the...

Descripción completa

Detalles Bibliográficos
Autores principales: ‘T Hart, Bert A., Jagessar, S. Anwar, Haanstra, Krista, Verschoor, Ernst, Laman, Jon D., Kap, Yolanda S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680746/
https://www.ncbi.nlm.nih.gov/pubmed/23781220
http://dx.doi.org/10.3389/fimmu.2013.00145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680746/
https://www.ncbi.nlm.nih.gov/pubmed/23781220
http://dx.doi.org/10.3389/fimmu.2013.00145

Ejemplares similares